Graft Polymer (UK) PLC - London-based developer and producer of alloyed polymers, biological supplements and drug delivery systems - Selects drug discovery solutions provider Eurofins Discovery to carry out initial testing for its co-lead aminoindane series, to begin immediately. First announced in July, the programme is under joint development with Awakn Life Sciences Corp and seeks to develop next-generation medicines targeting trauma-related mental health conditions like Post-Traumatic Stress Disorder. The condition affects about 20 million adults in the US, UK, and key European markets, Graft Polymer notes. Tests will assess the potential of Graft’s aminoindane series for serotonin, dopamine and noradrenaline reuptake inhibition. Selection marks a significant milestone, the company says, and follows its August announcement that it filed a new provisional patent in the US after Awakn ‘identified two aminoindane chemical series as co-leads for further development’.
Chief Executive Officer Anthony Tennyson CEO comments: ‘We are pleased with this development, Eurofins is an industry leader in drug discovery research. This marks an important step in our mission to bring new and innovative solutions to those suffering from trauma-related mental health disorders like PTSD. The expertise of Eurofins, combined with our collaborative approach with Awakn, puts us in an excellent position to advance this pre-clinical programme swiftly and effectively.’
Senior scientific advisor David Nutt adds: ‘The aminoindane series being developed shows great promise in modulating key neurotransmitter systems involved in mental health conditions like PTSD. By targeting serotonin, dopamine, and noradrenaline reuptake, this pharmacological testing could unlock new therapeutic pathways for addressing trauma-related disorders. We look forward to seeing the outcomes of this crucial pre-clinical stage.’
Current share price: 0.19 pence, closed up 4.4% in London on Friday
12-month change: down 89%
Copyright 2024 Alliance News Ltd. All Rights Reserved.
